Drug Clinical Trials:
News on drug clinical trials, articles on tests or new drugs and medication.
-
Nov 19th, 2008
Medical research is conducted in highly fragmented groups focusing on specific pathways or components leading to drugs that turn out not to work properly or to have dangerous side effects after cycles of animal and then clinical testing in humans.
-
Nov 19th, 2008
Big pharma has big problems. The root cause is a lack of research and development productivity, which means a dearth of new products to make up for looming patent expirations. Something near half of big pharma’s revenues will be threatened by generic competition within the next three to four years, and that will radically change the face of the industry.
-
Nov 12th, 2008
Potentia Pharmaceuticals presented Phase I data from the ASaP clinical trial for the company's leading drug candidate, POT-4, which is being developed for the treatment of AMD.
-
Nov 11th, 2008
VIA-2291, an investigational drug being developed by VIA Pharmaceuticals, significantly inhibited production of leukotrienes, proposed mediators of vascular inflammation, in patients with serious heart disease.
-
Nov 10th, 2008
Researchers reported on a study of a new oral anti-clotting agent — rivaroxaban — designed to identify doses that would be safe to test in subsequent Phase III efficacy and safety trials.
-
Nov 4th, 2008
PEGASYS (peginterferon alfa-2a) treatment regimens result in higher sustained virological response (SVR) rates for hepatitis C patients as compared to regimens with another pegylated interferon.
-
Oct 30th, 2008
Shire announced results from a 13-hour analog classroom study in school-aged children aged 6 to 12 years with Attention Deficit Hyperactivity Disorder (ADHD).
-
Oct 30th, 2008
SYMBICORT Inhalation Aerosol significantly improved lung function and was well-tolerated in patients with moderate to very severe Chronic Obstructive Pulmonary Disease (COPD) relative to budesonide and formotorol administered alone, and placebo.
-
Oct 30th, 2008
Data from a three-year study of patients with Chronic Obstructive Pulmonary Disease (COPD) found that the inhaled corticosteroid in Advair Diskus 250/50, fluticasone propionate, did not show an adverse effect on bone mineral density (BMD) measured at the lumbar spine and total hip compared to salmeterol alone
-
Oct 28th, 2008
Drug test volunteers should be given clearer, easier-to-understand information before signing up to take part.
